How many insider trades does FilingIQ track for KYTX?

FilingIQ tracks 45 Form 4 insider transactions for KYTX (Kyverna Therapeutics, Inc.), covering filings from Feb 12, 2024 onwards. 11 of those were filed in the last 90 days.

Are KYTX insiders net buyers or net sellers?

Across the full Form 4 history for KYTX, 7 transactions (16%) were open-market purchases and 1 (2%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does KYTX insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is KYTX in?

Kyverna Therapeutics, Inc. (KYTX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $438.11M.

KYTX insider trading

Healthcare

Kyverna Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

16% / 2%

Market cap

$438.11M

About Kyverna Therapeutics, Inc.

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Company website: kyvernatx.com

KYTX insider activity at a glance

FilingIQ has scored 45 insider transactions for KYTX since Feb 12, 2024. The most recent filing in our index is dated May 4, 2026.

Across the full history, 7 open-market purchases and 1 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on KYTX insider trades is 47.4/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live KYTX trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

13F funds holding KYTX

Casdin Capital, LLC

$4.31M · 0.3% of AUM

Frequently asked

How many insider trades does FilingIQ track for KYTX?: FilingIQ tracks 45 Form 4 insider transactions for KYTX (Kyverna Therapeutics, Inc.), covering filings from Feb 12, 2024 onwards. 11 of those were filed in the last 90 days.
Are KYTX insiders net buyers or net sellers?: Across the full Form 4 history for KYTX, 7 transactions (16%) were open-market purchases and 1 (2%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does KYTX insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is KYTX in?: Kyverna Therapeutics, Inc. (KYTX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $438.11M.

Methodology & sources

Every KYTX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.